WARF Therapeutics

Invest-Develop-Partner

Jump to section:

Deadline for fall project review: October 15; board review date is Nov. 18. Moving Translational Research Toward Patients

Mission: To partner with UW-Madison and Morgridge Institute for Research Principal Investigators (PIs) interested in translational research, invest to discover & develop novel drug-like molecules that modulate validated targets and improve human disease, and partner with Bio-centric companies to develop and commercialize

Bridging the Gap Between UW Discoveries and Pharma

UW-Madison and MIR PIs

Target Discovery

  • Novel Biological Target
  • Therapeutic Hypothesis
  • Rigorous Target Validation

WARF Therapeutics

Preclinical Drug Discovery

  • Preclinical Drug Discovery Experts
  • Project Management
  • Novel Intellectual Property (IP)

Virtual Laboratory

  • HTS, Fragment or Virtual Screening
  • Small Molecule Design & Optimization
  • In vivo PK/PD, Efficacy, Toxicology

Pharma, Biotech or Venture Capital Partners

Drug Development

  • IND Tox
  • Clinical Studies
  • NDA

WARF Therapeutics has built a virtual drug discovery laboratory through strategic partnerships with Sanford Burnham Prebys and contract research organizations.

For business questions, contact John Nagel or Rafael Diaz. If you are a PI interested in submitting your work to the program or talking through next steps, contact Jon Young. You do not need to have a patent, we are interested in talking with you about a new target early in your process.